ASCO 2021 Videos

Do Our Treatments Drive a New Resistant Mutational Phenotype? - Ana Aparicio

Single Priming Dose of 177Lu-PSMA-617 Followed by Pembrolizumab in mCRPC in a Phase 1b Trial - Rahul Aggarwal

Impact of Age on Castration Rates from The HERO Study – Michael Cookson

Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas

42-Month Follow-up of KEYNOTE-426, Pembrolizumab plus Axitinib First-Line Treatment for Advanced Renal Cell Carcinoma - Thomas Powles

Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris

Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor

Validating the Genomic Classifier to Identify Patients With a High Risk of Metastasis Among African American Men With Early Localized Prostate Cancer, VANDAAM Study – Kosj Yamoah

Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal

Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt

COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC, The COMBAT Study - Mark Markowski

Durability and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in the EV-103 Study in Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma – Terence W. Friedlander

Bladder-Sparing Treatment Options for Muscle-Invasive Bladder Cancer – Andrea Necchi

VEGF Blockade and Combination Therapeutic Options in Advanced Renal Cell Carcinoma - Andrea Apolo

Differences in the Pattern of and the Response to Treatment Not Just Race - Elisabeth Heath

Defining the Standard of Therapy for First-Line mHSPC - Lisa Horvath

The Addition of TAK-700 to Testosterone Suppression, Its Effect on Survival in mCSPC SWOG 1216 – Neeraj Agarwal

Case-Based Discussions Illuminate the Complexities of Oligometastatic Prostate Cancer Treatment - Phuoc Tran

The Importance of Bone-Protecting Agents When Treating mCRPC with Bone Metastatic Disease The PEACE III Trial – Silke Gillessen

The State of CRPC Treatment in Spain: Expert Opinions on Enzalutamide and Abiraterone - Elena Castro & Fernando Lopez-Campos

Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra

Impact of Age on Efficacy and Safety of Relugolix in the Phase 3 HERO Study Versus Leuprolide in Men with Advanced Prostate Cancer - Fred Saad

Updated Interim Efficacy and Safety Results from a Phase I/IIa Trial HPN424 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Tomasz Beer

Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer - Andrea Necchi

HCRN GU 16-257 a Phase 2 Trial of Gemcitabine, Cisplatin, Plus Nivolumab Shows Promise for Bladder-Sparing in Muscle- Invasive Bladder Cancer (MIBC)- Matthew Galsky

Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy As Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar

Updated Results from EV-201 Cohort 2 - Enfortumab Vedotin Is A Potential Non-Platinum Option for Cisplatin-Ineligible Patients Following Anti-PD-1/L1 Treatment - Bradley McGregor

Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark Fleming

Time to End of Next-Line Therapy in the JAVELIN Bladder 100 - Petros Grivas

Cisplatin and Gemcitabine With or Without Berzosertib in Patients with Advanced Urothelial Carcinoma - Tian Zhang

Longer-Term Outcomes of Patients with Testicular Cancer: Late Relapses and Toxicities - Sia Daneshmand

The Effect of Mandated Bone Protective Agents on Fracture Risk With Longer Follow-Up (EORTC 1333 / PEACE III Trial) – Fred Saad

Long-Term Follow-Up From the KEYNOTE-052 Trial, Pembrolizumab in the First-Line Setting in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer – Arjun Balar

Feladilimab Alone and in Combination with Pembrolizumab In Previously-Treated Urothelial Carcinoma Patients, An expansion Cohort of the INDUCE-1 Trial - Arjun Balar

PEACE-1 Trial Results: Abiraterone ± Radiotherapy in De Novo mCSPC – Karim Fizazi

Examining the Role of Docetaxel with Radiation Therapy and ADT in Non-Metastatic Prostate Cancer - Anthony D'Amico & Philip Kantoff

The VISION Trial Demonstrates 177Lu-PSMA-617 Significantly Improves Overall Survival and rPFS in mCRPC – Oliver Sartor

KEYNOTE-564 Demonstrates Improvement in Disease-Free Survival - A New Standard of Care for High-Risk Kidney Cancer - Rana McKay

177Lu-PSMA-617 Significantly Improves Overall Survival and Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer in VISION study - Mary-Ellen Taplin

177LuPSMA-617 - A New Standard of Care in the Treatment of mCRPC Based on The Phase III VISION Trial Results - Michael Morris

Determining Dose-Limiting Toxicity and Maximum Tolerated Dose of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer - Scott Tagawa

Feasibility of Neoadjuvant Nivolumab Without or With Lirilumab for Muscle-Invasive Bladder Cancer (PrE0807) – Petros Grivas

The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar

Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi

Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland

Apalutamide Improves Overall Survival and rPFS While Preserving Health-Related Quality of Life in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Neeraj Agarwal